STOCK TITAN

Madrigal Appoints Jacqualyn A. Fouse, Ph.D. to Its Board of Directors

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
management

Madrigal Pharmaceuticals (NASDAQ:MDGL) has appointed Jacqualyn "Jackie" Fouse, Ph.D. to its Board of Directors, while Fred Craves, Ph.D. will retire from the Board in July 2025. Fouse brings over 30 years of healthcare industry and finance experience, having previously served as CEO of Agios Pharmaceuticals and held executive positions at Celgene , Bunge , and Alcon Laboratories.

The appointment aligns with Madrigal's strategic focus on metabolic dysfunction-associated steatohepatitis (MASH). The company aims to drive the launch of Rezdiffra, their first approved MASH treatment, expand geographically, advance their clinical program in compensated MASH cirrhosis, and build their pipeline.

Madrigal Pharmaceuticals (NASDAQ:MDGL) ha nominato Jacqualyn "Jackie" Fouse, Ph.D. nel suo Consiglio di Amministrazione, mentre Fred Craves, Ph.D. si ritirerà dal Consiglio a luglio 2025. Fouse porta con sé oltre 30 anni di esperienza nel settore sanitario e finanziario, avendo precedentemente ricoperto il ruolo di CEO di Agios Pharmaceuticals e occupato posizioni dirigenziali in Celgene, Bunge e Alcon Laboratories.

La nomina si allinea con il focus strategico di Madrigal sulla steatoepatite associata a disfunzione metabolica (MASH). L'azienda mira a lanciare Rezdiffra, il loro primo trattamento MASH approvato, espandersi geograficamente, far progredire il loro programma clinico nella cirrosi MASH compensata e costruire il loro portafoglio.

Madrigal Pharmaceuticals (NASDAQ:MDGL) ha nombrado a Jacqualyn "Jackie" Fouse, Ph.D. en su Junta Directiva, mientras que Fred Craves, Ph.D. se retirará de la Junta en julio de 2025. Fouse aporta más de 30 años de experiencia en la industria de la salud y finanzas, habiendo sido anteriormente CEO de Agios Pharmaceuticals y ocupado cargos ejecutivos en Celgene, Bunge y Alcon Laboratories.

El nombramiento se alinea con el enfoque estratégico de Madrigal en la esteatohepatitis asociada a disfunción metabólica (MASH). La compañía tiene como objetivo impulsar el lanzamiento de Rezdiffra, su primer tratamiento MASH aprobado, expandirse geográficamente, avanzar en su programa clínico en cirrosis MASH compensada y construir su cartera.

마드리갈 제약 (NASDAQ:MDGL)은 Jacqualyn "Jackie" Fouse, Ph.D.를 이사회에 임명했으며, Fred Craves, Ph.D.는 2025년 7월 이사회에서 은퇴할 예정입니다. Fouse는 30년 이상의 의료 산업 및 금융 경험을 보유하고 있으며, 이전에 Agios Pharmaceuticals의 CEO로 재직했으며 Celgene, Bunge 및 Alcon Laboratories에서 임원직을 역임했습니다.

이번 임명은 마드리갈의 대사 기능 장애와 관련된 지방간염 (MASH)에 대한 전략적 초점과 일치합니다. 회사는 첫 번째 승인된 MASH 치료제인 Rezdiffra의 출시를 추진하고, 지리적으로 확장하며, 보상된 MASH 간경변에 대한 임상 프로그램을 발전시키고, 파이프라인을 구축하는 것을 목표로 하고 있습니다.

Madrigal Pharmaceuticals (NASDAQ:MDGL) a nommé Jacqualyn "Jackie" Fouse, Ph.D. à son conseil d'administration, tandis que Fred Craves, Ph.D. prendra sa retraite du conseil en juillet 2025. Fouse apporte plus de 30 ans d'expérience dans l'industrie de la santé et la finance, ayant précédemment été PDG d'Agios Pharmaceuticals et occupé des postes de direction chez Celgene, Bunge et Alcon Laboratories.

Cette nomination s'inscrit dans la stratégie de Madrigal axée sur la stéatohépatite associée à une dysfonction métabolique (MASH). L'entreprise vise à lancer Rezdiffra, son premier traitement MASH approuvé, à s'étendre géographiquement, à faire progresser son programme clinique sur la cirrhose MASH compensée et à développer son portefeuille.

Madrigal Pharmaceuticals (NASDAQ:MDGL) hat Jacqualyn "Jackie" Fouse, Ph.D. in seinen Vorstand berufen, während Fred Craves, Ph.D. im Juli 2025 aus dem Vorstand ausscheiden wird. Fouse bringt über 30 Jahre Erfahrung in der Gesundheitsbranche und im Finanzwesen mit, nachdem sie zuvor als CEO von Agios Pharmaceuticals tätig war und Führungspositionen bei Celgene, Bunge und Alcon Laboratories innehatte.

Die Ernennung steht im Einklang mit Madrigals strategischem Fokus auf metabolisch bedingte Steatohepatitis (MASH). Das Unternehmen zielt darauf ab, die Einführung von Rezdiffra, ihrer ersten genehmigten MASH-Behandlung, voranzutreiben, geografisch zu expandieren, ihr klinisches Programm bei kompensierter MASH-Zirrhose voranzubringen und ihre Pipeline auszubauen.

Positive
  • First company to achieve MASH treatment approval with Rezdiffra
  • Strategic board appointment bringing 30+ years of healthcare and finance expertise
  • Early launch success of Rezdiffra showing positive patient benefits
Negative
  • None.
  • Fred Craves, Ph.D. to retire from Madrigal’s Board of Directors in July 2025

CONSHOHOCKEN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced it has appointed Jacqualyn (“Jackie”) Fouse, Ph.D. to its Board of Directors. Fred Craves, Ph.D. is retiring from the Board in July 2025.

Julian Baker, Chairman of the Board of Directors, stated, “I am delighted to welcome Jackie Fouse to Madrigal. Jackie is an accomplished biotech executive who brings more than 30 years of healthcare industry and finance experience to the Madrigal Board. She will be a tremendous asset for Madrigal as the Company continues to grow and evolve.”

Mr. Baker continued, “On behalf of the Board, I would like to thank Fred Craves for his many years of service to Madrigal. From the outset of the Company through today, Fred’s leadership has been an invaluable part of Madrigal’s success.”

Bill Sibold, Chief Executive Officer of Madrigal, added, “Jackie Fouse’s appointment to our Board of Directors reflects Madrigal’s commitment to long-term leadership in MASH. I look forward to working with her to drive the launch of Rezdiffra, expand geographically, advance our clinical program in compensated MASH cirrhosis, and build our pipeline. I’d also like to thank Fred Craves for the instrumental role he has played at Madrigal for more than 15 years.”

Dr. Fouse was previously Chief Executive Officer of Agios Pharmaceuticals from 2019 to 2022 and currently serves as the Chair of the Board of Agios. Prior to joining Agios, she served in executive leadership roles at Celgene Corporation including President and Chief Operating Officer, President, Global Hematology & Oncology, and Chief Financial Officer. Before joining Celgene, Dr. Fouse served as chief financial officer of Bunge Limited, a leading global agribusiness and food company. Prior to Bunge, she served as Senior Vice President, Chief Financial Officer, and Head of Corporate Strategy at Alcon Laboratories, a leading ophthalmic pharmaceutical and medical device company. Prior to her tenure with Alcon, she held a variety of senior leadership roles with international companies. Dr. Fouse earned her B.A. and M.A. in economics and a Ph.D. in finance from the University of Texas at Arlington. She also holds an M.S. in environmental management from Yale and an M.S. in wildlife forensics and conservation from the University of Florida.

Dr. Fouse stated, “I am thrilled to be joining the Board of Directors of Madrigal, a company that has transformed care for patients with MASH. After years of challenges and setbacks in MASH drug development, Madrigal broke through with the first approved treatment, and the early launch of Rezdiffra has demonstrated the compelling benefit that this innovative medicine represents for patients. I look forward to working with this team that has successfully developed and launched Rezdiffra to deliver on Madrigal’s growth objectives in the years ahead.”

About Madrigal
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by the FDA for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c). For more information, visit www.madrigalpharma.com.

Forward Looking Statements
This press release includes “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended, including statements related to the launch of Rezdiffra and its expected use for treating MASH with moderate to advanced fibrosis, Madrigal’s aspirations to be the leading company in the MASH sector, and Madrigal’s plans to expand to Europe. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to: the assumptions underlying the forward-looking statements; risks of obtaining and maintaining regulatory approvals, including, but not limited to, potential regulatory delays or rejections; the challenges with the commercial launch of a new product, particularly for a company that does not have commercial experience; our history of operating losses and the possibility that we may never achieve or maintain profitability; risks associated with meeting the objectives of Madrigal’s clinical trials, including, but not limited to Madrigal’s ability to achieve enrollment objectives concerning patient numbers (including an adequate safety database), outcomes objectives and/or timing objectives for Madrigal’s trials; any delays or failures in enrollment, and the occurrence of adverse safety events; risks related to the effects of Rezdiffra’s (resmetirom’s) mechanism of action; enrollment and trial conclusion uncertainties; market demand for and acceptance of Rezdiffra; the potential inability to raise sufficient capital to fund ongoing operations as currently planned or to obtain financing on acceptable terms; our ability to service indebtedness and otherwise comply with debt covenants; outcomes or trends from competitive trials; future topline data timing or results; our ability to prevent and/or mitigate cyber-attacks; the timing and outcomes of clinical trials of Rezdiffra (resmetirom); the uncertainties inherent in clinical testing; uncertainties concerning analyses or assessments outside of a controlled clinical trial; and changes in laws and regulations applicable to our business and our ability to comply with such laws and regulations. Undue reliance should not be placed on forward looking statements, which speak only as of the date they are made. Madrigal undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events. Please refer to Madrigal’s submissions filed with the U.S. Securities and Exchange Commission(“SEC”), for more detailed information regarding these risks and uncertainties and other factors that may cause actual results to differ materially from those expressed or implied. Madrigal specifically discusses these risks and uncertainties in greater detail in the sections appearing in Part I, Item 1A of its Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on February 26, 2025, and as updated from time to time by Madrigal’s other filings with the SEC.

Investor Contact
Tina Ventura, IR@madrigalpharma.com

Media Contact
Christopher Frates, media@madrigalpharma.com


FAQ

When will Fred Craves retire from Madrigal Pharmaceuticals' (MDGL) Board of Directors?

Fred Craves will retire from Madrigal's Board of Directors in July 2025.

What is Jacqualyn Fouse's previous experience before joining MDGL's board?

She was CEO of Agios Pharmaceuticals (2019-2022) and held executive roles at Celgene , Bunge , and Alcon Laboratories.

What are Madrigal Pharmaceuticals' (MDGL) current strategic priorities?

Madrigal focuses on launching Rezdiffra, expanding geographically, advancing their MASH cirrhosis clinical program, and building their pipeline.

What is Rezdiffra and what was its significance for MDGL?

Rezdiffra is Madrigal's first approved treatment for MASH, marking a breakthrough after years of challenges in MASH drug development.
Madrigal Pharmac

NASDAQ:MDGL

MDGL Rankings

MDGL Latest News

MDGL Stock Data

7.19B
20.14M
8.74%
105.1%
17%
Biotechnology
Pharmaceutical Preparations
Link
United States
WEST CONSHOHOCKEN